232 related articles for article (PubMed ID: 10337502)
1. Effects of propionyl-L-carnitine on peripheral arterial obliterative disease of the lower limbs: a double-blind clinical trial.
Dal Lago A; De Martini D; Flore R; Gaetani E; Gasbarrini A; Gerardino L; Pola R; Santoliquido A; Serricchio M; Tondi P; Nolfe G
Drugs Exp Clin Res; 1999; 25(1):29-36. PubMed ID: 10337502
[TBL] [Abstract][Full Text] [Related]
2. [Treatment of chronic arterial occlusive disease of the lower limbs with propionyl-1-carnitine in elderly patients].
Terranova R; Luca S
Minerva Med; 2001 Feb; 92(1):61-6. PubMed ID: 11317141
[TBL] [Abstract][Full Text] [Related]
3. Propionyl-L-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study.
Brevetti G; Perna S; Sabbá C; Martone VD; Condorelli M
J Am Coll Cardiol; 1995 Nov; 26(6):1411-6. PubMed ID: 7594063
[TBL] [Abstract][Full Text] [Related]
4. Effect of propionyl-L-carnitine on a background of monitored exercise in patients with claudication secondary to peripheral artery disease.
Hiatt WR; Creager MA; Amato A; Brass EP
J Cardiopulm Rehabil Prev; 2011; 31(2):125-32. PubMed ID: 20861750
[TBL] [Abstract][Full Text] [Related]
5. Propionyl-L-carnitine in Leriche-Fontaine stage II peripheral arterial obstructive disease.
Allegra C; Antignani PL; Schachter I; Koverech A; Messano M; Virmani A
Ann Vasc Surg; 2008; 22(4):552-8. PubMed ID: 18502605
[TBL] [Abstract][Full Text] [Related]
6. Propionyl l-carnitine: intermittent claudication and peripheral arterial disease.
Andreozzi GM
Expert Opin Pharmacother; 2009 Nov; 10(16):2697-707. PubMed ID: 19827991
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the efficacy of propionyl-L-carnitine versus pulsed muscular compressions in diabetic and non-diabetic patients affected by obliterating arteriopathy Leriche stage II.
Riccioni C; Sarcinella R; Palermo G; Izzo A; Liguori M; Koverech A; Messano M; Virmani A
Int Angiol; 2008 Jun; 27(3):253-9. PubMed ID: 18506129
[TBL] [Abstract][Full Text] [Related]
8. [Comparison between L-propionyl carnitine and physical-rehabilitative exercise in diabetics with obliterative arteriopathy of the legs (Fontaine's stage IIa)].
Costanza G; Di Salvo A; Barone G; Verruso G; Zamueli M; Marchese G
Minerva Cardioangiol; 1999 Dec; 47(12):649-50. PubMed ID: 10670244
[No Abstract] [Full Text] [Related]
9. The action of propionyl-L-carnitine on the vasal endothelium: increased t-PA synthesis and a decrease in the activity of PAI-1. A preliminary study.
Pola P; De Martini D; Gerardino L; De Rossi S; Tondi P
Drugs Exp Clin Res; 1992; 18(8):343-8. PubMed ID: 1292917
[TBL] [Abstract][Full Text] [Related]
10. Carnitine and peripheral arterial disease.
Hiatt WR
Ann N Y Acad Sci; 2004 Nov; 1033():92-8. PubMed ID: 15591006
[TBL] [Abstract][Full Text] [Related]
11. [The clinical and hemodynamic effects of propionyl-L-carnitine in the treatment of congestive heart failure].
Pucciarelli G; Mastursi M; Latte S; Sacra C; Setaro A; Lizzadro A; Nolfe G
Clin Ter; 1992 Nov; 141(11):379-84. PubMed ID: 1493661
[TBL] [Abstract][Full Text] [Related]
12. Propionyl-L-carnitine.
Wiseman LR; Brogden RN
Drugs Aging; 1998 Mar; 12(3):243-8; discussion 249-50. PubMed ID: 9534023
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic effects of L-carnitine and propionyl-L-carnitine on cardiovascular diseases: a review.
Ferrari R; Merli E; Cicchitelli G; Mele D; Fucili A; Ceconi C
Ann N Y Acad Sci; 2004 Nov; 1033():79-91. PubMed ID: 15591005
[TBL] [Abstract][Full Text] [Related]
14. [Conservative therapy of arterial occlusive diseases. Double-blind study on the effect of butalamine hydrochloride].
Seboldt H
Fortschr Med; 1980 Feb; 98(7):257-60. PubMed ID: 6767648
[TBL] [Abstract][Full Text] [Related]
15. [Double-blind randomized controlled trial of ifenprodil tartrate versus placebo in chronic arterial occlusive disease of the legs at stage II of the Leriche and Fontaine classification].
Branchereau A; Rouffy J
J Mal Vasc; 1995; 20(1):21-7. PubMed ID: 7745355
[TBL] [Abstract][Full Text] [Related]
16. Propionyl-L-carnitine for intermittent claudication.
Deckert J
J Fam Pract; 1997 Jun; 44(6):533-4. PubMed ID: 9191622
[No Abstract] [Full Text] [Related]
17. Rheological activity of propionyl L-carnitine.
Pola P; Flore R; Tondi P; Nolfe G
Drugs Exp Clin Res; 1991; 17(3):191-6. PubMed ID: 1914846
[TBL] [Abstract][Full Text] [Related]
18. L-Carnitine plus cilostazol versus cilostazol alone for the treatment of claudication in patients with peripheral artery disease: a multicenter, randomized, double-blind, placebo-controlled trial.
Goldenberg NA; Krantz MJ; Hiatt WR
Vasc Med; 2012 Jun; 17(3):145-54. PubMed ID: 22615190
[TBL] [Abstract][Full Text] [Related]
19. [Experiences with solcoseryl in treatment of stage II peripheral arterial occlusive disease--assessment of clinical effectiveness].
Horsch S; Claeys L
Vasa Suppl; 1992; 35():151-2. PubMed ID: 1481024
[No Abstract] [Full Text] [Related]
20. Effect of glutathione infusion on leg arterial circulation, cutaneous microcirculation, and pain-free walking distance in patients with peripheral obstructive arterial disease: a randomized, double-blind, placebo-controlled trial.
Arosio E; De Marchi S; Zannoni M; Prior M; Lechi A
Mayo Clin Proc; 2002 Aug; 77(8):754-9. PubMed ID: 12173710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
